# Table of Contents

- TABLE OF CONTENTS .......................................................................................................................... 2
- CLASSIFICATION OF TREATMENT TYPES ...................................................................................... 3
- ABOUT THE COVID-NMA PROJECT ................................................................................................. 12
- DISCLAIMER ...................................................................................................................................... 12
## Classification of treatment types

| Treatment type               | Treatment name                                                                 |
|------------------------------|--------------------------------------------------------------------------------|
| Drugs                        |                                                                                |
| Antiviral, non-specific      | Interferons                                                                    |
|                              | Interferon lambda alpha 1a                                                   |
|                              | Immunoglobulin                                                                 |
|                              | Interleukin-2                                                                 |
| Antiviral, broad spectrum    | Favipiravir                                                                     |
|                              | Ribavirin                                                                      |
|                              | Triazavirin                                                                    |
|                              | Umifenovir                                                                     |
|                              | Sofosbuvir+Daclatasvir                                                         |
|                              | Sofosbuvir+Ledipasvir                                                          |
|                              | Umifenovir+ribavirin                                                           |
|                              | Xiyanping                                                                      |
|                              | Nitazoxanide                                                                   |
|                              | Galidesivir                                                                    |
| Antiviral, antiretrovirals    | ASC09                                                                          |
|                              | Azvudine                                                                       |
|                              | Danoprevir                                                                     |
|                              | Darunavir                                                                      |
|                              | Darunavir+cobicistat                                                           |
|                              | Lopinavir+ritonavir                                                            |
|                              | Remdesivir                                                                     |
|                              | Danoprevir+ritonavir                                                           |
|                              | ASC09+ritonavir                                                                |
|                              | Clevudine                                                                      |
| Treatment type                                                                 | Treatment name                                                                 |
|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Other antiviral                                                                | Baloxavir marboxil                                                             |
|                                                                                | Oseltamivir                                                                     |
|                                                                                | BLD-2660                                                                        |
| Antiviral combination (when combining antivirals from different groups)        | interferon alpha+lopinavir                                                     |
|                                                                                | umifenovir+interferon alpha                                                     |
|                                                                                | Lopinavir+ritonavir+Ribavirin+interferon beta1                                  |
|                                                                                | ASC09F+oseltamivir                                                              |
|                                                                                | Ritonavir+oseltamivir                                                          |
|                                                                                | lopinavir+ritonavir+xiyanping                                                   |
|                                                                                | Lopinavir+ritonavir+interferon beta1                                            |
| Antimalaria                                                                    | Chloroquine                                                                     |
|                                                                                | Hydroxychloroquine                                                              |
|                                                                                | Dihydroartemisinin                                                              |
|                                                                                | Mefloquine                                                                      |
|                                                                                | GNS561 (chloroquine analog)                                                     |
| Antimalaria+antibiotics                                                        | Hydroxychloroquine+azithromycin                                                |
| Antibiotics+antimalaria+monoclonal antibodies                                   | Azithromycin+hydroxychloroquine+tocilizumab                                    |
| Antibiotics                                                                    | Carrimycin                                                                      |
|                                                                                | Ceftriaxone                                                                     |
|                                                                                | Levofloxacin OR Moxifloxacin                                                    |
|                                                                                | Piperacillin+Tazobactam                                                         |
|                                                                                | Ceftaroline fosamil                                                             |
|                                                                                | Amoxicillin+potassium clavulanate                                               |
|                                                                                | Standard course macrolide                                                       |
|                                                                                | Teicoplanin                                                                     |
|                                                                                | Azithromycin                                                                    |
| Treatment type                  | Treatment name                                |
|--------------------------------|-----------------------------------------------|
| Antiparasitics                 | Suramin sodium                                |
|                                | levamisole pill                               |
|                                | Senicapoc                                     |
|                                | Niclosamide                                   |
|                                | Nitazoxanide                                  |
|                                | Ivermectin                                    |
| Antimalaria+antiparasitics     | Hydroxychloroquine+ivermectin                 |
| Antifungal                     | Itraconazole                                  |
| Non-specific anti-inflammatory | Methylprednisolone                            |
|                                | Ciclesonide                                   |
|                                | Dexamethasone                                 |
|                                | budesonide+formoterol                         |
|                                | Hydrocortisone                                |
|                                | Other corticosteroids                         |
|                                | Prednisone                                    |
| Anti-inflammatory              | Colchicine                                    |
|                                | Piclidenoson                                  |
| Immunosuppressant              | Fingolimod                                    |
|                                | Leflunomide                                   |
|                                | Thalidomide                                   |
| Immunosuppressant+antiviral    | Thalidomide+umifenovir                        |
| Kinase inhibitor               | Jakotinib hydrochloride                       |
|                                | Ruxolitinib                                   |
|                                | Nintedanib esilate                            |
|                                | Imatinib mesylate                             |
|                                | Acalabrutinib                                 |
| Treatment type                                      | Treatment name                                                                 |
|----------------------------------------------------|-------------------------------------------------------------------------------|
| Non-specific anti-inflammatory+immunosuppressant   | Methylprednisolone+tacrolimus                                                 |
| Protease inhibitor                                 | Camostat Mesilate                                                            |
| Monoclonal antibodies                              | Adalimumab                                                                   |
|                                                    | Bevacizumab                                                                  |
|                                                    | Camrelizumab                                                                 |
|                                                    | Eculizumab                                                                   |
|                                                    | Mepolizumab                                                                  |
|                                                    | PD-1 mAb                                                                     |
|                                                    | Sarilumab                                                                    |
|                                                    | Tocilizumab                                                                  |
|                                                    | Adamumab + tozumab                                                           |
|                                                    | Ixekizumab                                                                   |
|                                                    | nivolumab                                                                    |
|                                                    | IFX-1                                                                        |
|                                                    | Leronlimab (PRO 140)                                                         |
|                                                    | Clazakizumab                                                                 |
| Antiviral+ Monoclonal antibodies                   | Favipiravir+tocilizumab                                                      |
| Antiviral+antimalaria                              | darunavir+cobicistat+hydroxychloroquine                                      |
|                                                    | favipiravir+chloroquine phosphate                                            |
| Immunomodulator                                    | CD24                                                                         |
|                                                    | Anakinra                                                                     |
| ACE inhibitor                                      | Losartan                                                                     |
|                                                    | Recombinant human angiotensin-converting enzyme 2 (rhACE2)                   |
|                                                    | Telmisartan                                                                  |
| Treatment type       | Treatment name                                                                 |
|----------------------|-------------------------------------------------------------------------------|
|                      | Valsartan                                                                      |
|                      | Renin-Angiotensin-System-Blockade                                            |
|                      | Captopril                                                                      |
| Antiarrhythmic       | Amiodarone                                                                     |
| Calcium channel blocker | Verapamil                                                                    |
| Vasodilator          | angiotensin 1-7                                                                |
| Cardio protective    | aspirin + clopidogrel + rivaroxaban + atorvastatin + omeprazole               |
| Anticoagulant        | Enoxaparin sodium                                                              |
|                      | Rivaroxaban                                                                    |
|                      | Tinzaparin                                                                     |
| Antiviral+antihistamine | Ebastine+interferon alpha                                                     |
| NSAID                | Ibuprofen                                                                      |
|                      | Naproxen                                                                       |
| Mucolytic            | Acetylcysteine                                                                 |
|                      | Bromhexine hydrochloride                                                       |
| Antidepressant       | Fluvoxamine                                                                    |
| Other                | Aviptadil (vasoactive intestinal peptide)                                      |
|                      | Bismuth potassium citrate (may inhibit SARS-CoV1 helicase)                    |
|                      | Dipyridamole (antiplatelet)                                                    |
|                      | Pirfenidone (treat idiopathic pulmonary fibrosis)                              |
|                      | Polyinosinic-polycytidylic acid                                                |
|                      | rhG-CSF                                                                        |
|                      | Thymosin                                                                       |
|                      | Tranilast                                                                      |
| Treatment type | Treatment name |
|----------------|----------------|
|                | Ulinastatin (sepsis management) |
|                | Vitamin C |
|                | Sodium Aescinate (vasoactive, organ protective) |
|                | Tetrandrine (calcium channel blocker, anti-inflammatory) |
|                | Lipoic acid injection (antioxidant) |
|                | PUL-042 Inhalation Solution |
|                | Noscapine (narcotine derivative) |
|                | T89 (improving oxygen saturation) |
|                | Naproxen+lansoprazole |
|                | Neurokinin-1 antagonist |
|                | Deferoxamine |
|                | Rabeprazole (proton pump inhibitor) |
|                | Compound amino acid |
|                | Tranexamic acid |
|                | Nitric Oxide Releasing Solution |
|                | Zinc chloride |
|                | Selinexor |
|                | T3 solution for injection |
|                | Curcumin C3 |
|                | Berberine |
|                | Pyridostigmine |
|                | Dalargin |
|                | Febuxostat |
|                | Vazegepatn |
|                | Dapagliflozin |
| Vaccine        | BCG vaccine |
|                | Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) |
| Treatment type     | Treatment name                                                                 |
|-------------------|-------------------------------------------------------------------------------|
|                   | bacTRL-Spike vaccine                                                         |
|                   | ChAdOx1 nCoV-19 vaccine                                                       |
|                   | CIGB 2020 vaccine                                                            |
| Non-drug          | Advanced Therapy Medicinal Products (ATMP)                                    |
|                   | Aerosol inhalation of vMIP: viral macrophage inflammatory protein             |
|                   | Ankylosaurus; M1 macrophages target                                           |
|                   | Anti-2019-nCoV inactivated convalescent plasma                                |
|                   | Anti-SARS-CoV-2 inactivated convalescent plasma                               |
|                   | Biological preparation of human placenta                                      |
|                   | Convalescent plasma treatment                                                 |
|                   | Cord blood mesenchymal stem cells                                             |
|                   | Human menstrual blood-derived stem cells                                      |
|                   | Immunoglobulin from cured patients                                           |
|                   | Inactivated Mycobacterium vaccine                                             |
|                   | Infusion of convalescent plasma                                               |
|                   | Mesenchymal stem cells                                                        |
|                   | Mesenchymal stem cells exosomes atomization                                   |
|                   | mRNA-1273                                                                     |
|                   | NK cells                                                                      |
|                   | Plasma treatment                                                              |
|                   | Recombinant cytokine gene-derived protein injection                           |
|                   | Regulating intestinal flora                                                   |
|                   | Therapeutic antibody from recovered novel coronavirus pneumonia patients       |
|                   | Umbilical cord blood mononuclear cells                                        |
|                   | Umbilical cord mesenchymal stem cells (hucMSCs)                               |
| Treatment type          | Treatment name                                                                 |
|------------------------|-------------------------------------------------------------------------------|
|                        | Umbilical cord Wharton’s Jelly derived mesenchymal stem cells                 |
|                        | Umbilical Cord (UC)-derived mesenchymal stem cells                            |
|                        | human dental pulp stem cells                                                  |
|                        | Sargramostim (rhu GM-CSF)                                                     |
|                        | Recombinant super-compound interferon (rSIFN-co)                              |
|                        | Convalescent anti-SARS-CoV-2 plasma                                            |
|                        | Mycobacterium                                                                  |
|                        | Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs)          |
|                        | Bone marrow-derived mesenchymal stem cell                                      |
| Metabolomic group      | Compound amino acid                                                           |
| rearrangement          |                                                                               |
| Protective device      | Wear a self-made "gastroscopy mask" during gastroscopy                        |
|                        | Medical mask                                                                   |
|                        | N95 respirator                                                                 |
| Infection prevention   | Propofol anesthesia maintenance, common extubation                            |
|                        | Propofol anesthesia was maintained, and the extubation strategy of "circulatory induced respiration" was adopted after the operation |
|                        | Sevoflurane anesthesia was maintained, and the extubation strategy of "circulatory induced respiration" was adopted after the operation |
| Rehabilitation         | Shadowboxing                                                                  |
|                        | pulmonary rehabilitation                                                       |
| Treatment type        | Treatment name                                                                 |
|----------------------|-------------------------------------------------------------------------------|
|                      | Lung rehabilitation training                                                   |
|                      | Exercise rehabilitation under remote monitoring                               |
|                      | Patient education                                                             |
| Gas inhalation       | Nitric oxide gas                                                              |
|                      | Oxygen concentrator                                                           |
|                      | Hydrogen-Oxygen Nebulizer                                                     |
|                      | Hydrogen inhalation                                                           |
|                      | Continuous positive airway pressure                                            |
|                      | Hyperbaric oxygen                                                             |
| Respiratory support  | high-flow therapy by nasal cannulae (HFNC)                                    |
|                      | bag-valve mask oxygenation (SMO)                                               |
|                      | High flow nasal oxygen                                                        |
|                      | Postural positioning                                                          |
| Life support         | Renal replacement therapy                                                      |
|                      | Artificial liver therapy                                                      |
|                      | ozonated autohemotherapy                                                       |
|                      | ECMO implantation                                                             |
|                      | CytoSorb-Therapy                                                              |
|                      | HA330                                                                         |
| Microbiota intervention | Probiotics                                                                   |
|                      | Newgen beta-gluten probiotic composite powder                                 |
|                      | Washed microbiota transplantation                                              |
|                      | Regulating intestinal flora                                                    |
| Medical device       | ultra short wave electrotherapy                                               |
|                      | Inspiratory training                                                          |
|                      | Expiratory training device                                                     |
## COVID Classification of treatment types

### 28 April 2020

| Treatment type | Treatment name                                      |
|----------------|-----------------------------------------------------|
| Mouthwash      | Povidone-iodine                                     |
|                | Hydrogen peroxide                                   |
|                | Neem extract (Azadirachta indica)                   |
| Education      | Training for wearing mask                           |

**DISCLAIMER:** These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or noninfringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

For additional information please consult the COVID-NMA project site.

### ABOUT THE COVID-NMA PROJECT

The COVID-NMA project is led by [international team of researchers](https://www.cochrane.org) from Cochrane (Cochrane France, Cochrane Germany, Cochrane Ireland etc) as well as from the université de Paris and other universities.

A living mapping of all ongoing research on Covid-19 is available and updated every week. The team is also reporting and synthesising the data from the randomised trials every 3 days.

### DISCLAIMER

This website and/or database of the World Health Organization (collectively “WHO Site”) may contain links to websites, databases and/or materials developed, sponsored or maintained by third parties unaffiliated with the World Health Organization (collectively, “Third Party Sites”).

The World Health Organization (WHO) provides links to Third Party Sites solely as a convenience to users of this WHO Site. WHO makes no (and hereby disclaims any) representations, warranties or guarantees of any kind (whether express or implied) as
COVID Classification of treatment types
28 April 2020

The inclusion of links to any Third Party Sites shall not create any liability for WHO arising from or relating to any such links, Third Party Sites and/or any content provided therein or accessible therefrom, and your use of any and all of the foregoing is entirely at your own risk and responsibility. Accordingly, you forever hold WHO harmless from any and all claims, liabilities and/or obligations of any kind arising from or in connection with the use of any such links, Third Party Sites and/or content provided therein or accessible therefrom.

WHO reserves the right, in its sole discretion, to discontinue links to any Third Party Sites at any time for any reason. Should you leave the WHO Site via a link contained herein, the content you view in any Third Party Site is not provided or controlled by WHO. The inclusion on this WHO Site of a link to any Third Party Site does not constitute, and shall not be construed as, an endorsement, approval or recommendation by WHO of such Third Party Site and/or of any content, goods or services provided thereon or accessible therefrom.